Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04138-5
Abstract: Trastuzumab emtansine (T-DM1) is the standard treatment in the current second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, a useful therapy after T-DM1 resistance has not been established. In… read more here.
Keywords: combination; resistant cells; dm1; trastuzumab emtansine ... See more keywords
Study of the properties of doxorubicin-resistant cells affected by acute leucosis
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Bioenergetics and Biomembranes"
DOI: 10.1007/s10863-017-9738-4
Abstract: The stiffness of cell membrane was found to be one of the factors determining resistance of a cell in vitro to antibiotic doxorubicin action. Membranes of surviving cells are negatively charged (−35 – −30 mV) and… read more here.
Keywords: resistant cells; cells affected; affected acute; study properties ... See more keywords
A Strategy to Delay the Development of Cisplatin Resistance by Maintaining a Certain Amount of Cisplatin-Sensitive Cells
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-00422-2
Abstract: Cisplatin (ddp), which is commonly employed in the treatment of many advanced cancers, often results in initial therapeutic success; however, rapid progression of ddp-resistant cells remains the main reason for treatment failure. Facd with such… read more here.
Keywords: resistant cells; ddp; treatment; cisplatin ... See more keywords
De novo regulation of RD3 synthesis in residual neuroblastoma cells after intensive multi-modal clinical therapy harmonizes disease evolution
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-48034-2
Abstract: Most high-risk neuroblastomas that initially respond to therapy will ultimately relapse. Currently, no curative treatment is available. Acquired genetic/molecular rearrangement in therapy-resistant cells contributes to tumor relapse. Recently, we identified significant RD3 loss in progressive… read more here.
Keywords: resistant cells; disease; therapy; rd3 ... See more keywords
KLF5-mediated aquaporin 3 activated autophagy to facilitate cisplatin resistance of gastric cancer
Sign Up to like & getrecommendations! Published in 2022 at "Immunopharmacology and Immunotoxicology"
DOI: 10.1080/08923973.2022.2122498
Abstract: Abstract Background Resistance to chemotherapeutic drugs limits the control of gastric cancer (GC) development. The study intended to probe into the mechanism of aquaporin 3 (AQP3) on the chemoresistance of GC. Methods Cisplatin (CDDP)-resistant cells… read more here.
Keywords: cddp resistant; resistant cells; cddp; klf5 ... See more keywords
Inhibition of lncRNA NEAT1 sensitizes medulloblastoma cells to cisplatin through modulating the miR-23a-3p-glutaminase (GLS) axis.
Sign Up to like & getrecommendations! Published in 2022 at "Bioengineered"
DOI: 10.1080/21655979.2021.2008695
Abstract: Medulloblastoma (MB) is a commonly occurring brain malignancy in adolescence. Currently, the combination of chemotherapy with subsequent irradiation is a regular therapeutic strategy. However, high dosage of chemotherapy is associated with drug resistance and side… read more here.
Keywords: mir 23a; cells cisplatin; resistant cells; cisplatin resistant ... See more keywords
SHR-A1403, a novel c-Met antibody-drug conjugate, overcomes AZD9291 resistance in NSCLC cells overexpressing c-Met.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer science"
DOI: 10.1111/cas.14180
Abstract: EGFR tyrosine kinase inhibitors (TKIs) have been used as the first-line treatment of non-small cell lung cancers (NSCLCs) harboring EGFR-activating mutations, while acquired resistance is ubiquitous and needs to be solved urgently. Here, we introduce… read more here.
Keywords: resistant cells; cells overexpressing; overexpressing met; resistance ... See more keywords
PO-472 Chemotherapy resistance-associated epithelial to endothelial transition in gastric cancer
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.492
Abstract: Introduction Gastric cancer (GC) is the fifth most common cancer worldwide and the third leading cause of cancer-related deaths. To date, gastrectomy and chemotherapy are the only therapeutic options, but drug resistance is the main… read more here.
Keywords: chemotherapy; resistant cells; 472 chemotherapy; gastric cancer ... See more keywords
Downregulation of LINC01857 Increases Sensitivity of Gastric Carcinoma Cells to Cisplatin
Sign Up to like & getrecommendations! Published in 2022 at "Computational and Mathematical Methods in Medicine"
DOI: 10.1155/2022/3325686
Abstract: Background The critical roles of long noncoding RNAs (lncRNAs) in the carcinogenesis and progression of cancers have been well documented. It was reported that lncRNAs were involved in chemotherapy resistance in various cancers. This study… read more here.
Keywords: cell; resistant cells; gastric carcinoma; linc01857 ... See more keywords
A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-17-0560
Abstract: Mounting evidence suggests that the Hippo coactivator Yes-associated protein 1 (YAP1) is a major mediator of cancer stem cell (CSC) properties, tumor progression, and therapy resistance as well as often a terminal node of many… read more here.
Keywords: yap1; resistant cells; esophageal adenocarcinoma; adenocarcinoma ... See more keywords
Abstract 1897: Mechanism of MEK inhibitor resistance in triple negative breast cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-1897
Abstract: Background: Triple-negative breast cancer (TNBC) is an aggressive disease associated with recurrence, metastasis, and resistance to chemotherapy and radiation; effective targeted therapies are needed. Although the MEK inhibitors (MEKi) selumetinib (AZD6244) and pimasertib (AS703026) showed… read more here.
Keywords: resistant cells; meki resistant; inhibitor; mechanism ... See more keywords